Intranasal capsaicin

Phase 1Small molecule

TThe University of Texas Health Science Center, Houston

Intranasal capsaicin is one of 12 small molecule programs targeting Biomarker. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BiomarkerEnrolling by invitation

BiomarkerPhase 1

Enrolling by invitation

Competition

Competitive Landscape

13 competitors in Biomarker

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

2 2

Nucala

GGlaxo Dba Glaxosmithkline

Approved

1 3

Ibrance

Pfizer

Phase 2

2 4

Acthar

MMallinckrodt

Phase 3

1 5

PD-1 Blocking Antibody

SSun Yat-sen University

Phase 2

1 6

Hyperpolarized Xenon-129

TThunder Bay Regional Health Research Institute

Phase 3

1 7

Aspercreme Warming

AAveritas Pharma, Inc.

Phase 1

1 8

Galunisertib

Eli Lilly

Phase 2

1 9

Somavert

PPharmacia and Upjohn

Preclinical

1 10

Intranasal capsaicin

TThe University of Texas Health Science Center, Houston

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Allergic Rhinitis1 trial

The Prevalence of Local Immunoglobulin E (IgE) Elevation and Its Effect on Intranasal Capsaicin Therapy in the Non-allergic Rhinitis Population

Completed·TThe University of Texas Health Science Center, Houston·Phase 3·NCT05093478·28 enrolled

Biomarker1 trial

Pain Biomarker Study

Enrolling by invitation·TThe University of Texas Health Science Center, Houston·Phase 1·NCT03511846·371 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Intranasal capsaicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intranasal capsaicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intranasal capsaicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe University of Texas Health Science Center, Houston

Intranasal capsaicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Allergic Rhinitis1 trial

Biomarker1 trial

References

Drug Info

Quick Facts

Related News